Biotech · Public company · Seattle, WA, US
Adaptive Biotechnologies Corp
Ticker ADPT · SEC CIK 0001478320
Track this companyFree. Adds Adaptive Biotechnologies Corp to your Dealase workspace and tells you when its record changes.
Clinical trials135 recruiting or active
Pipeline programs5From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline5
- ClonoSEQFollicular LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- clonoSEQ AssayAcute Lymphoblastic Leukemia, Adult B-CellClinicalTrials.gov · fetched Nov 12, 2026
- T-Detect COVID testCovid19ClinicalTrials.gov · fetched Nov 12, 2026
- T-Detect LymeLyme DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- T-Detect™ SARS-CoV-2 AssayCoronavirus Disease (COVID-19)ClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials13
- A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHPPHASE2 · RECRUITING · started Sep 4, 2025ClinicalTrials.gov NCT06828991 · fetched Nov 12, 2026
- Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell LymphomaPHASE2 · RECRUITING · started Jun 11, 2024ClinicalTrials.gov NCT06252675 · fetched Nov 12, 2026
- ImmuneSense™ IBD StudyTERMINATED · started Oct 31, 2022ClinicalTrials.gov NCT05769829 · fetched Nov 12, 2026
- Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR TherapyRECRUITING · started Jun 1, 2022ClinicalTrials.gov NCT05255354 · fetched Nov 12, 2026
- Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell TransplantACTIVE_NOT_RECRUITING · started Apr 20, 2022ClinicalTrials.gov NCT05271630 · fetched Nov 12, 2026
- ImmuneSense™ COVID-19 Cross-Reactivity StudyWITHDRAWN · started Dec 15, 2021ClinicalTrials.gov NCT05112874 · fetched Nov 12, 2026
- ImmuneSense COVID-19 Variant StudyCOMPLETED · started Oct 12, 2021ClinicalTrials.gov NCT05054088 · fetched Nov 12, 2026
- The clonoSEQ® Watch RegistryTERMINATED · started Oct 13, 2020ClinicalTrials.gov NCT04545333 · fetched Nov 12, 2026
- ImmuneSense™ COVID-19 StudyCOMPLETED · started Oct 9, 2020ClinicalTrials.gov NCT04583982 · fetched Nov 12, 2026
- ImmuneSense Lyme StudyCOMPLETED · started Jul 9, 2020ClinicalTrials.gov NCT04422314 · fetched Nov 12, 2026
- Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With VenetoclaxPHASE2 · ACTIVE_NOT_RECRUITING · started May 13, 2020ClinicalTrials.gov NCT04419519 · fetched Nov 12, 2026
- ImmuneRACE - Immune Response Action to COVID-19 EventsCOMPLETED · started Apr 24, 2020ClinicalTrials.gov NCT04494893 · fetched Nov 12, 2026
- Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)PHASE2 · COMPLETED · started Sep 14, 2015ClinicalTrials.gov NCT02553642 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Nov 4, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 4, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 4, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 29, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 22, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 15, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 9, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 5, 2026 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Feb 26, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Feb 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jan 12, 2026 · fetched Nov 12, 2026